Angele Kelder Department of Hematology VU University Medical Center Biography Publications Institution JoVE Articles Angele Kelder has not added a biography. If you are Angele Kelder and would like to personalize this page please email our Author Liaison for assistance. Publications Leukemic Stem Cell Frequency: a Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia PloS One. 2014 | Pubmed ID: 25244440 A Phase 2 Study of Bortezomib Combined with Either Idarubicin/cytarabine or Cytarabine/etoposide in Children with Relapsed, Refractory or Secondary Acute Myeloid Leukemia: a Report from the Children's Oncology Group Pediatric Blood & Cancer. Oct, 2014 | Pubmed ID: 24976003 High Class II-associated Invariant Chain Peptide Expression on Residual Leukemic Cells is Associated with Increased Relapse Risk in Acute Myeloid Leukemia Leukemia Research. Jun, 2014 | Pubmed ID: 24731748 Normal Hematopoietic Stem Cells Within the AML Bone Marrow Have a Distinct and Higher ALDH Activity Level Than Co-existing Leukemic Stem Cells PloS One. 2013 | Pubmed ID: 24244383 Interleukin-2 Receptor Alpha-chain (CD25) Expression on Leukaemic Blasts is Predictive for Outcome and Level of Residual Disease in AML European Journal of Cancer (Oxford, England : 1990). Jun, 2009 | Pubmed ID: 19321337 Correlation of Minimal Residual Disease Cell Frequency with Molecular Genotype in Patients with Acute Myeloid Leukemia Haematologica. Jan, 2009 | Pubmed ID: 19042917 Identification of a Small Subpopulation of Candidate Leukemia-initiating Cells in the Side Population of Patients with Acute Myeloid Leukemia Stem Cells (Dayton, Ohio). Dec, 2008 | Pubmed ID: 19096043 Positive Selection for CD90 As a Purging Option in Acute Myeloid Leukemia Stem Cell Transplants Cytometry. Part B, Clinical Cytometry. Jan, 2008 | Pubmed ID: 18061946 High Stem Cell Frequency in Acute Myeloid Leukemia at Diagnosis Predicts High Minimal Residual Disease and Poor Survival Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Sep, 2005 | Pubmed ID: 16166428 Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia Jacqueline Cloos*1,2, Jeffrey R. Harris*3, Jeroen J.W.M. Janssen1, Angele Kelder1, F. Huang3, Gerrit Sijm1, Maike Vonk1, Alexander N. Snel1, Jennifer R. Scheick1, Willemijn J. Scholten1, Jannemieke Carbaat-Ham1, Dennis Veldhuizen1, Diana Hanekamp1, Yvonne J.M. Oussoren-Brockhoff1, Gertjan J.L. Kaspers2,4, Gerrit J. Schuurhuis1, A. Kate Sasser3, Gert Ossenkoppele1 1Department of Hematology, VU University Medical Center, 2Pediatric Oncology/Hematology, VU University Medical Center, 3Janssen Research & Development, LLC, 4Princess Máxima Center for Pediatric Oncology JoVE 56386 Ricerca sul cancro
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia Jacqueline Cloos*1,2, Jeffrey R. Harris*3, Jeroen J.W.M. Janssen1, Angele Kelder1, F. Huang3, Gerrit Sijm1, Maike Vonk1, Alexander N. Snel1, Jennifer R. Scheick1, Willemijn J. Scholten1, Jannemieke Carbaat-Ham1, Dennis Veldhuizen1, Diana Hanekamp1, Yvonne J.M. Oussoren-Brockhoff1, Gertjan J.L. Kaspers2,4, Gerrit J. Schuurhuis1, A. Kate Sasser3, Gert Ossenkoppele1 1Department of Hematology, VU University Medical Center, 2Pediatric Oncology/Hematology, VU University Medical Center, 3Janssen Research & Development, LLC, 4Princess Máxima Center for Pediatric Oncology JoVE 56386 Ricerca sul cancro